A phase I study of the first in class dual IMiD/bromodomain inhibitor N-methyl-2-pyrrolidone (NMP) in relapsed and refractory multiple myeloma.

首个同类双 IMiD/溴结构域抑制剂 N-甲基-2-吡咯烷酮 (NMP) 治疗复发性和难治性多发性骨髓瘤的 I 期研究。

• 批准号: nhmrc : 1067516
• 负责人: A/Pr Jake Shortt
• 金额: $ 36.74万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/phase-i-study-multiple-myeloma/455311
• 关键词: phase; study; first; class; dual

We have newly discovered that a simple molecule called NMP has the ability to control myeloma cells that have become resistant to other available treatments. NMP works by enhancing immune function and by killing myeloma cells directly by inhibiting survival signals. NMP is different from all other types of available myeloma treatments. We intend to test the safety and power of NMP in the treatment of myeloma by running a clinical trial of NMP in patients with relapsed myeloma.

我们新发现，一个称为NMP的简单分子具有控制对其他可用疗法具有抗性的骨髓瘤细胞的能力。 NMP通过增强免疫功能并通过抑制生存信号直接杀死骨髓瘤细胞来起作用。 NMP与所有其他类型的可用骨髓瘤疗法不同。我们打算通过在复发性骨髓瘤患者中进行NMP的临床试验来测试NMP在骨髓瘤治疗骨髓瘤方面的安全性和能力。